Name:
Institution:
Type:
PI
Grant Award Details
Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis
Grant Type:
Grant Number:
CLIN1-09472
Project Objective:
File an IND with the US FDA by 3/31/2018
Investigator:
Disease Focus:
Bone or Cartilage Disease
Osteoarthritis
Human Stem Cell Use:
Adult Stem Cell
Cell Line Generation:
Other
Award Value:
$1,200,000
Status:
Closed
Grant Application Details
Application Title:
- Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis
Public Abstract:
Therapeutic Candidate or Device
Intra-articularly injected allogeneic culture-expanded human adipose derived mesenchymal progenitor cells
Indication
Knee osteoarthritis
Therapeutic Mechanism
Cartilage regeneration (as determined by cartilage volume increase), immunomodulatory effects
Unmet Medical Need
There is no approved disease modification therapy for osteoarthritis (OA), and OA is a leading cause of both hospitalization and joint replacement surgery. Our product provides symptom relief and structure modification benefits.
Project Objective
File IND
Major Proposed Activities
- Manufacture product to supply the proposed trial
- Complete non-clinical safety study requested by the FDA
- File IND
Statement of Benefit to California:
California spends more on osteoarthritis (OA) management than any other state in the union and financial and human cost of OA is expected to worsen with the upward trend in obesity and the ageing baby boomer generation. Our allogenic adipose-derived mesenchymal progenitor cells has the potential to reduce the need for total knee joint replacement, offer a viable regenerative treatment for OA, and significantly reduce healthcare costs in California. .
